stockportfolio.pro
Olema Pharmaceuticals, Inc. (OLMA)
Healthcare · Biotechnology · NasdaqGS
Olema Pharmaceuticals, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-4.32M | $-22.12M | $-71.10M | $-104.79M | $-96.66M | $-129.47M | $-162.45M |
| Net margin | — | — | — | — | — | — | — |
Source: Olema Pharmaceuticals, Inc. SEC filings (10-K).
Explore 7 years of Olema Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OLMA in your portfolio →
Olema Pharmaceuticals, Inc. financial history by metric
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. — frequently asked questions
What is Olema Pharmaceuticals, Inc.'s revenue?
Olema Pharmaceuticals, Inc. (OLMA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Olema Pharmaceuticals, Inc. profitable?
No — OLMA reported a net loss of $-162.45M in fiscal 2025.
What is OLMA's P/E ratio?
Olema Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Olema Pharmaceuticals, Inc. have?
As of fiscal year 2025, OLMA carried roughly $3.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Olema Pharmaceuticals, Inc.'s market cap?
Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of about $835.04M, based on the latest data in our nightly-refreshed cache.
When does Olema Pharmaceuticals, Inc.'s fiscal year end?
OLMA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Olema Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.